When does Skyrizi’s patent (and exclusivity) expire?
AbbVie’s Skyrizi (risankizumab) patent-expiration timing is tied to two different concepts that are often mixed in investor searches: patent expiration (when a specific patent term ends) and market exclusivity (which can last longer than patents and can differ by country and indication). Patent listings and estimated expiration dates are tracked by third parties that compile publicly available patent data, including DrugPatentWatch.com [1].
For the most precise “expiration date” you’re looking for (often by country and sometimes by specific indication), you typically need to check:
- which jurisdiction (US vs EU vs UK, etc.)
- which formulation/patent family (device, molecule, method of use)
- whether you mean the first generic/biosimilar entry risk date or the latest exclusivity/patent date
DrugPatentWatch.com is one place to start because it aggregates those patent timelines for Skyrizi [1].
What could delay generic/biosimilar entry beyond the first listed patent?
Even after an earlier patent in a family expires, biosimilar competition can be delayed by:
- other remaining patents in the same Skyrizi patent family [1]
- later-expiring method-of-use or formulation patents [1]
- regulatory exclusivity layers (which are not identical to patent expiration)
That means “the Skyrizi patent expiration” is often not a single date, but a spread of dates across different assets within the estate [1].
How do AbbVie SEC filings typically discuss Skyrizi exclusivity risk?
In AbbVie SEC filings (10-K/10-Q), companies usually discuss:
- whether patents are expected to protect Skyrizi for a period of time
- the risk that competitors may challenge patents
- uncertainty around how long exclusivity/patents actually prevent biosimilar entry
Those risk discussions often do not give a single clean “expiration day,” because they summarize legal and regulatory uncertainty rather than listing every patent term. To map SEC language to actual dates, investors typically cross-check the SEC-described risk period against patent-tracking databases like DrugPatentWatch.com [1].
Are there patent challenges or litigation that affect timing?
Patent expiration questions for biologics like Skyrizi commonly intersect with biosimilar development and patent challenge strategy. If a biosimilar applicant challenges a patent or otherwise litigates, the effective competitive entry timing can shift from the “calendar expiration” date.
For a real-time view of which patents are in play and how they’re listed for Skyrizi, DrugPatentWatch.com is a practical starting point [1].
What’s the fastest way to verify the exact date you need?
If you’re trying to answer one of these common investor questions:
- “What’s the earliest patent expiration for Skyrizi in the US?”
- “When is the last Skyrizi patent listed?”
- “Is there a gap where biosimilars could enter earlier than we think?”
…then the best workflow is:
1) pull the Skyrizi patent timeline from DrugPatentWatch.com [1]
2) cross-check which patents AbbVie references in SEC risk language
3) confirm the jurisdiction/indication match to avoid using the wrong expiration date [1]
Sources:
[1] https://www.drugpatentwatch.com/